Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Craig Hallum

Stock analysts at Craig Hallum started coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a report issued on Friday. The brokerage set a “buy” rating and a $15.00 price target on the stock. Craig Hallum’s target price points to a potential upside of 136.59% from the company’s previous close.

Other research analysts have also issued research reports about the stock. William Blair began coverage on shares of Compass Therapeutics in a research report on Monday, January 5th. They set an “outperform” rating on the stock. Wall Street Zen cut Compass Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, February 8th. Citigroup assumed coverage on shares of Compass Therapeutics in a report on Wednesday, December 3rd. They set an “outperform” rating for the company. Canaccord Genuity Group set a $13.00 price objective on Compass Therapeutics in a research note on Wednesday, February 4th. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $9.00 target price on shares of Compass Therapeutics in a research report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Compass Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $13.00.

Compass Therapeutics Trading Down 1.6%

Compass Therapeutics stock opened at $6.34 on Friday. The stock’s 50 day moving average is $5.65 and its 200-day moving average is $4.47. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -14.09 and a beta of 1.46. Compass Therapeutics has a 12 month low of $1.33 and a 12 month high of $6.88.

Institutional Investors Weigh In On Compass Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CMPX. Suvretta Capital Management LLC raised its holdings in shares of Compass Therapeutics by 97.2% in the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock valued at $49,354,000 after purchasing an additional 6,951,666 shares during the last quarter. Vivo Capital LLC lifted its stake in Compass Therapeutics by 57.9% in the third quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after purchasing an additional 3,502,000 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Compass Therapeutics by 45.6% during the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock valued at $24,720,000 after buying an additional 2,212,794 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in Compass Therapeutics by 11.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock valued at $11,505,000 after purchasing an additional 449,868 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Compass Therapeutics by 19.0% during the 4th quarter. Geode Capital Management LLC now owns 3,502,526 shares of the company’s stock valued at $18,813,000 after buying an additional 558,057 shares in the last quarter. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.